The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings.Targeting treatment to children 1-11 months old could reduce antimicrobial resistance by limiting antibiotic distributions while treating children at the highest mortality risk. However, this targeted intervention has not yet been tested. The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of biannual azithromycin distribution on mortality as well as determine the impact of age-based targeting on antimicrobial resistance.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
All-cause Mortality (1-59 Months Old)
Timeframe: from 6 months up to 2.5 years
All-cause Mortality (1-11 Months Old)
Timeframe: from 6 months up to 2.5 years
All-cause Mortality (12-59 Months Old)
Timeframe: from 6 months up to 2.5 years
Prevalence of Resistance to Macrolides - Nasopharyngeal Swabs (1-59 Months Old)
Timeframe: After 4 distributions (approximately 24 months)
Load of Genetic Determinants of Resistance to Macrolides - Rectal Swabs (1-59 Months Old)
Timeframe: After 4 distributions (approximately 24 months)